Development of novel antivirals for arthritogenic alphaviruses

Active Grant Awarded Last action

Award ID
R01AI187483
Recipient
Awarding agency
Obligated
$2,013,899

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 23% complete
Place of performance
Louisville, KY 40202, USA

Award details come from USAspending.gov.

Description

Abstract
Development of antivirals for arthritogenic alphaviruses this NIH grant proposal aims at the optimization of a new world (NW) alphavirus-specific quinazoline scaffold for the development of an anti-old world (OW) arthritogenic alphavirus therapeutic candidate. With a particular focus on chikungunya virus and other alphaviruses with a pandemic potential, this project responds to an urgent public health need for effective antiviral treatments for OW alphaviruses, given the recent increase in global prevalence of OW alphavirus infections. DR. Chung's research group has made significant advancements in developing a quinazolinone-based antiviral specifically targeting NW alphaviruses like venezuelan equine encephalitis virus, exhibiting remarkable efficacy in preclinical models. This success, coupled with the compound's unique mechanism of action targeting the viral replicase complex, positions the quinazoline scaffold as a valid starting point for developing effective antivirals for other alphaviruses. However, the compound series necessitates significant enhancement in potency against OW alphaviruses. The team has identified a key residue that contributes to the NW alphavirus-specific antiviral spectrum. Here by elucidating the molecular interactions and clashes between the quinazolinone scaffold and OW alphavirus replicase complexes, the team aims to develop next- generation inhibitors with enhanced efficacy toward OW arthritogenic alphaviruses. Recognizing the need to enhance the potency of the quinazoline series against OW alphaviruses, the project proposes three specific aims undertaking a comprehensive and systemic approach integrating structural insights, medicinal chemistry, and preclinical evaluations. DR. LUO's work in specific aim 1 focuses on mapping molecular interactions and clashes between the current quinazolinone scaffold and the OW alphavirus replicase complex, providing critical structural insights that will inform the design of new inhibitors in specific aim 2 led by DR. Bannister. Specific aim 2 efforts are directed towards identifying chemical groups leading to resistance in OW alphaviruses, designing and synthesizing new compounds tailored for OW alphaviruses, and ultimately developing lead candidates with optimized pharmacological profiles. DR. Chung, in specific aim 3, will assess these novel antivirals in vitro and in vivo, supporting the structure-activity study for AIM2. Aim 3 will also study the mechanisms of action and resistance of the series. The overarching goal of the project is to deliver novel, potent therapeutic candidates for OW arthritogenic alphaviruses. With a highly integrated team of experts and a meticulous approach spanning molecular structural biology, medicinal chemistry, and virology, this project holds the promise of advancing preclinical development, ultimately addressing a critical GAP in public health preparedness against OW alphavirus infections. Upon successful completion, the project will deliver promising therapeutic candidates ready for advanced preclinical development to address the critical needs for arthritogenic alphaviruses therapeutics.

Transactions

Action Obligated Date
Amendment $133,920
Amendment Development of novel antivirals for arthritogenic alphaviruses - this NIH grant proposal aims at the optimization of a new world (NW) alphavirus-specific… $597,529
Amendment $140,400
Original award $544,521

Subawards

Subrecipient Amount Awarded
Nanyang Technological University Start date: 09/24/2025-08/31/2026 Scope of work: Dr. Dahai Luo, associate professor at Nanyang Technical University (NTU), will conduct a research project under… $140,400
University Of Florida Scope of Work: The project will investigate and optimize structure–activity relationships (SAR) within quinazoline and proline amide lead series to identify and… $236,030

Quick answers

Who received award R01AI187483?

R01AI187483 was awarded to University Of Louisville by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 24, 2025.

How much is award R01AI187483 worth?

$2,013,899 has been obligated on R01AI187483.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award